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SUMMARY
Introduction: In spite of recent treatment advances, lung cancer continues to be the first world cancer related death cause;
its mortality associated occupied the fifth place in Colombia in 2004. Complete surgical resection is the therapeutic option with
the greatest cure probability, however it results frequently ineffective given the current incapacity in Colombia to an early
detection of the disease. This study reports the characterization of a group of 30 lung cancer patients regarding the gene dose
(gene copy number) found at the loci corresponding to genes EGFR (erb B1), PIK3CA and C-myc in tumor samples, and
compares the results with the dose found in adjacent lung from the same patients.
Methods: The gene dose of EGFR (erbB1), PIK3CA, and C-myc were measured by real time PCR in matched tumor and
normal lung tissue samples. Results are expressed as the multiplicity of each gene dose with respect to a single copy reference
gene. In this case the gene HHB (human hemoglobin). Antiquity of the cases ranged from 5 to 10 years.
Results: An increased gene dose for EGFR and PIK3CA was a feature clearly associated to the tumor phenotype of the
sample (found in 96 and 100% of the tumors respectively). Quantitative measure of this feature demonstrated for both genes
a high sensitivity and specificity for tumor/normal discrimination as confirmed by the ROC analysis. On the other hand, the
Spearman test showed a great correlation between EGFR and PIK3CA doses (ρ=0.75). C-myc was the gene whose dose was
less consistently correlated to the tumor phenotype, however most of the patients with amplified C-myc presented distant
spread of tumor cells (metastasis) at diagnosis.
Conclusion: Quantitative measurement of EGFR, PIK3CA, and C-myc gene dose by real time PCR provides a method for
tumor phenotype recognition in DNA samples from lung tissue. These markers can be considered at the construction of a marker
panel for lung cancer detection on alternative, non-invasive clinical samples. However clinical value will depend on the use
of additional molecular markers, some of which could be of epigenetic character.
Keywords: Lung cancer; Gene dose; Oncogenes; Real time PCR; EGFR; PIK3CA; C-myc
Amplificación oncogénica como marcador tumoral en un grupo de pacientes con cáncer pulmonar
RESUMEN
Introducción: A pesar de los avances terapéuticos actuales, el cáncer de pulmón sigue como la primera causa de muerte
por cáncer en el mundo, ocupando Colombia el quinto lugar en mortalidad por este tipo de afección en el 2004. La resección
quirúrgica total es la alternativa terapéutica con mayores probabilidades de curaciones, pero resulta poco efectiva en el país
por la incapacidad actual para detectar tempranamente la enfermedad. Este trabajo informa la caracterización de un grupo de
30 pacientes con cáncer de pulmón con referencia a la dosis génica hallada en los loci correspondientes a los genes EGFR
(erb B1), PIK3CA y C-myc en muestras tumorales, comparada con la dosis encontrada en el tejido normal adyacente de los
mismos enfermos.
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Métodos: La dosis génica se midió en cada caso por PCR
en tiempo real sobre ADN aislado de tejido tumoral y normal
preservado en parafina de cada paciente. Los resultados se
expresan como el número de veces que la dosis de cada gen
sobrepasa la dosis de un gen de referencia, en este caso el
HHB (hemoglobina humana β). El rango de antigüedad de los
casos fue de 5 a 10 años.
Resultados: Una dosis génica incrementada para los
genes EGFR, PIK3CA demostró ser una característica clara-
mente asociada con el fenotipo tumoral (96% y 100% de los
tumores respectivamente). La medición cuantitativa de dicho
fenómeno demostró en ambos casos gran sensibilidad y
especificidad para la discriminación tumor/normal como lo
confirma el análisis ROC. Por otro lado, la amplificación
simultánea de ambos genes en el mismo paciente fue un hecho
observado con alta frecuencia (Spearman=0.75). La dosis de
C-myc mostró una asociación menos consistente con el
carácter tumoral, sin embargo todos los pacientes con C-myc
amplificado presentaron dispersión distante de células
tumorales (metástasis).
Conclusión: La detección cuantitativa del estado de
amplificación de los genes EGFR, PIK3CA y C-myc por PCR
en tiempo real provee un medio sensible para reconocer el
fenotipo tumoral en muestras de ADN extraído de tejido
pulmonar. Estos marcadores podrían considerarse en el desa-
rrollo de sistemas de detección (paneles) orientados a mues-
tras clínicas alternativas como el plasma sanguíneo. Sin
embargo, la definición de un panel de marcadores con valor
clínico requiere el estudio de marcadores adicionales entre los
cuales podrían incluirse algunos de tipo epigenético.
Palabras clave: Cáncer de pulmón; Dosis génica;
Oncogenes; PCR en tiempo real; EGFR; PIK3CA;
C-myc.
Lung cancer is the first cancer related death cause
worldwide, with and still increasing incidence1. Although
other cancers are diagnosed at higher rates in Colombian
population, as normally occurs in developing countries,
it is considered a public health priority since life
expectation when diagnosed continues to be very limited
(around 10%), and current diagnosis and treatment
strategies have not produced the expected impact on
these rates. In year 2000, lung cancer was third among
neoplastic diseases in men (2493 cases) while in women
it was sixth (1509 cases)1. Diverse genetic and epigenetic
alterations affect cell genome during carcinogenesis.
Gene amplification, understood as gene copy number
increase at specific genomic regions, has been normally
observed during the adaptative response to physiological
stress as one of the mechanisms by which synthesis of
certain gene products is favored at quantities exceeding
transcriptional capacity of just one copy2. Gene
amplification is part of the normal development program
of many organisms, however in mammals it is observed
as a response to some cytotoxic agents or as a tumor
development associated phenomenon3.
Gene copy number is a feature that can be easily
evaluated in tumor isolated DNA with common molecular
techniques; suggesting a great potential as neoplastic
marker. A conveniently selected panel of these markers
could be used to detect and recognize the tumor
phenotype both in high risk people given their exposure
to known risk factors and in people who are suspected
to have the disease although at an early stage non easily
detectable by TAC or radiography. In addition, given the
high correlation between epigenetic and genetic
alterations occurring in lung tumor cells and those
detectable in circulating cell free DNA from patients4,
this approach could be applied on clinical samples whose
obtainment is less invasive than biopsies like plasma or
sputum5. With this in mind, identification of molecular
markers demonstrating high sensitivity and specificity
for tumor phenotype recognition, easily testable by
routine lab assays, is an important step for the construction
of valuable diagnostic tools.
The present study characterized a group of lung
cancer patients at various clinical stages, based on
paraffin preserved tissue samples from lung cancer
patients. Markers selected for the study were genes
EGFR, PIK3CA, and C-myc, three components of the
EGFR-PIK3CA-AKT signaling pathway. This pathway
is known since its deregulation in tumor cells, which
generally implies an increase of signal transmission,
leads to the adoption of a pro-apoptotic signals non
responsive phenotype6.
MATERIALS AND METHODS
Population and inclusion criteria. This paper
reports the characterization of a group of patients with
primary lung cancer regarding the gene dose at loci
corresponding to EGFR, PIK3CA and C-myc genes in
tumor cells, compared with those found in adjacent lung
tissue with normal phenotype from the same patients.
This is a descriptive cross-sectional study analyzing a 30
cases sample including patients with any of the following
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histological lung cancer subtypes: Squamous carcinoma
(SQ), adenocarcinoma (AC), large cell carcinoma
(LCC), and small cell carcinoma (SCC) (Table 1).
Cases were provided by the Pathology Departments of
Hospital Santa Clara ESE (Bogotá) and the Fundación
Santafé de Bogotá (FSFB). Both materials and patients
information were handled according to the scientific
committees of the institutions. Paraffin blocks containing
representative amounts of tumor or normal tissue from
each patient were selected and tissues were micro-
dissected and processed separately. Patient age ranged
between 39 and 79 years at diagnosis, however segment
from 65 to 74 years included most of them (Table 1).
DNA isolation from paraffin embedded tissue.
Three sequential sections were obtained from every
paraffin block. First was 3 μm thick, CritiSolve
deparaffinized (Fisher Scientific, Waltham MA. USA),
H&E stained and used to delimit suitable tissue areas.
Remaining cuts were 10 μm, equally treated and used to
collect tumor and normal lung from corresponding areas
for processing.
Tissues collected from sections 2 and 3 were
incubated in 100 mM Tris-HCl (pH 7.2), 10 mM EDTA,
55 μg/ml yeast tRNA, and 2.2 μg/μl Proteinase K
(FERMENTAS, Glen Burnie, MD, USA) during 16 h.
Then the enzyme was heated and inactivated for 10 min
at 100°C. DNA was recovered by standard phenol-
chloroform extraction and ethanol precipitation. DNA
amount was quantified by real time PCR using control
commercial human DNA as amplification reference
(PROMEGA, Madison WI, USA) and an Alu PCR
target sequence7. Primers and amplification conditions
were as previously presented by Weisenberger, et al.,
for amplicon named Alu-C48.
Measurement of gene copy numbers. Gene copy
number measurement was performed through the relative
comparison with the dose of a reference gene. The gene
chosen as reference in this study was the gene coding
for human hemoglobin beta chain (HHB). Measurement
of both reference and target genes was performed by
real time PCR with the SyberGreen technology in a
LightCycler® 2.0 equipment, using the LightCycler®
FastStart DNA Master SYBR Green I Kit (Cat.
12015099001) and the LightCycler® Control Kit DNA
(Cat. 12158833001), all from ROCHE. The second Kit
allowed the construction of a calibration curve for the
reference gene linking the CT values generated by the
equipment with known concentrations of template DNA.
Then, all isolated DNA samples were subjected to real
time PCR for the reference gen and the obtained CTs
were interpolated in the standard curve.
The same technique was used to amplify genes
EGFR, PIK3CA and C-myc, on every patient normal
and tumor DNA isolates in addition to the control non-
tumor DNA from the kit, and the resulting CT values
were compared with the matched CT values for HHB.
The analysis was performed with the LightCycler 4.0
software (ROCHE) using the Relative Quantification
Monocolor protocol. This analysis allowed to obtain
gene dose for the target genes expressed as the number
of times each gene dose exceeds that of the reference
gene.
PCR conditions were as follows: 95°C - 5 min for
initial denaturation; followed by 45 cycles of 95°C-15
seconds, 60°C-30 seconds and 72°C-10 seconds. Pri-
mer sequences both for the target genes and the reference
gene are shown in Table 2. Every reaction was mounted
in a final volume of 20 μl, primer concentration was
always 1 μM and remaining reagents were added
according to manufacturer indications. Each run included
positive and negative controls, reference gene calibrators
and calibrators for the target gene.
Statistical analysis. Specificity and sensitivity of a
gene dose increase as neoplastic marker can be expressed
as the fraction of pathologically determined tumor tissues
of the group where measured gene dose exceeds a
given threshold. These are so considered «true positives»
as determined by the molecular assay. Similarly, the
«true negatives» are those samples whose detected
amplification level is lower than the threshold and this
feature coincides with a «normal» phenotype diagnosed
by the pathologist. Since for the present study there are
no available «thresholds» for each marker gene, a
receiver operating characteristic analysis (ROC) was
applied to the gene dose measurements. The ROC
analysis allows locating a threshold so that the number
of true positives and negatives is as high as possible.
ROC curves, graphs that illustrate the behavior of
the specificity and sensitivity of phenotype recognition
as the threshold moves along the range, where used
observe the capacity of each marker to discriminate
DNA isolates obtained from tumor and normal tissues.
Two kind of analysis were performed: The first included
tumor and normal tissues from the whole group of cases,
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Table 1
Patient characteristics and gene dose found
Case code              Gen    Age     Meta          EGFRb               PIK3CAb                 C-mycb
                              Tumor    Normal       Tumor     Normal Tumor    Normal
a.  Metastasis reported   b . Gene dose expressed as a multiple of the matched dose of gene HHB.    NA  Non available data
Adenocarcinomas
 1 AT M NA - 28.5 2.1 8.8 1.2 0,69 1.36
 13 AT F 64 + 28.02 NA 5.25 1.34 10.01 2.65
 11 AT F 27 + 2.05 3.29 NA NA 4.02 0.83
 129 AT F 67 - 28.0 1.18 9.5 1.04 2.33 2.61
 47 AT M 39 NA NA NA 4.02 1.36 9.98 1.57
 25 AT F 70 + 16.01 2.1 8.7 NA 8.62 1.22
 34 AT F 75 - 87.69 1.95 3.71 1.18 4.32 0.18
 4 AT F 63 - NA 2.46 5.45 0.9 2.83 1.56
 42 AT F 63 + 11.35 1.95 3.89 1.45 14.33 1.82
 56 AT M 47 + 7.96 0.39 NA NA 16.99 0.68
 81 AT F 72 + 25.76 1.75 7.23 1.98 14.53 1.28
 92 AT M 39 - 16.01 1.2 NA 1.25 8.62 NA
 122 AT F 63 - 36.59 2.16 5.25 0.86 1.22 3.44
 120 AT M 62 + NA NA 4.02 1.13 1.37 2.67
 2 AT F 78 - 25.37 2.92 3.48 1.23 9.84 1.11
 96 AT M 64 - 37.79 2.46 5.75 4.02 0.39 0.1
Squamous carcinomas
 108 QT F 64 + 16.2 3.19 2.08 NA 2.46 1.82
 45 QT M 69 - 42.06 NA 5.24 1.87 1,38 0.72
 15 QT M 79 + 45.52 1.95 58.4 NA 64.95 0.87
 48 QT M 70 - 35.09 NA NA 5.22 NA NA
 123 QT M 73 - 60.22 1.12 5.18 1.15 1.76 3.65
 57 QT M 50 - 90.95 1.68 NA 1.25 1.32 1.56
 67 QT M 47 - 23.63 1.26 NA NA 0.86 1.13
 82 QT M 56 NA 62.32 0.38 NA NA 1.18 0.98
 98 QT F 39 NA 25.7 NA 5.03 1.21 1.82 1.51
Large cell
 65 LT (64) NA NA + 30.29 0.81 NA 1.19 97.5 1.67
 76 LT (11) M 46 + 82.28 NA 9.5 0.92 105 1.76
Small cell lung cancer
 116 ST F 44 + 9.28 30.29 NA NA 97.29 0.72
Carcinoid
 118 CT F 42 - 86.16 NA 11.31 1.2 3.65 1.3
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the second only included cases was carried out on the
cases diagnosed as SQ or AC, the most frequent
subtypes among the group. This tool can be also used to
assess the sensitivity and specificity of a marker to
discriminate tumors with different histological subtypes.
A marker with a «perfect» discriminatory power
(sensitivity and specificity of 100%) generates a ROC
curve crossing the upper left corner of the graph, so that
the area under the curve (AUC) matches 100% of the
unit. An AUC equal or slightly higher than 50 % (0.5)
indicates a very low sensitivity and specificity of the
assay9.
Gene dose results for each marker were also
correlated as function of the phenotype by means of the
Wilcoxon signed rank test. The utilization of a non-
parametric test is necessary given the high frequency on
zero values among the data (no gene dose increase) that
does not allows to meet the requirement of the data to
be «normally distributed». p values lower than 0.01 were
considered significant.
Finally, a Spearman analysis was used to find any
correlation of the gene dose with the age of the patients.
A correlation coefficient (ρ) close to the lower or upper
limits of the range (1> ρ>1) indicates a strong negative
or positive correlation between the variables respectively.
On the contrary, a ñ value close to zero (0) indicates that
a significant correlation is not supported by the results.
All the analysis described was performed with the
software JMP 7.0 (SAS Institute).
RESULTS
This study reports the relative quantification of the
genomic dose of EGFR, PIK3CA and C-myc in tumors
and matched normal lung tissue from 30 lung cancer
cases with diverse pathological diagnoses. Both the
reference HHB gene and the three target genes were
Real Time PCR detected on both human control genomic
DNA and isolates from tumor and normal tissues from
each patient in order to obtain a relative quantification of
the genomic dose increase. The estimation was finally
achieved by interpolation in a standard curve.
Graphic 1 shows the gene dose values of genes
EGFR, PIK3CA, and C-myc related to the dose of HHB.
Gene HHB is one of the most widely used reference
genes, since its gene dose (2 copies, by human diploid
genome) is rarely altered with neoplastic transfor-
mation10. In tumor samples the detected EGFR gene
dose ranged from 2 to 90 times that of HHB. 60% of the
cases located the 20-40 interval. On the contrary, not
any of the normal matched tissues significantly differed
from the reference value (Graphic 1, Panel A). The
corresponding ROC graph shows a high capacity of this
gene for tumor origin identification in DNA isolates,
which is confirmed by an AOC value close to 1. The
Wilcoxon test yielded a p<0,0001 for the discrimination
between tumor and normal samples.
PIK3CA demonstrated a similar behavior. It showed
a good capacity for tumor/normal discrimination
Table 2
Primers for the genes evaluated
   Gene          Sequence
 C-myc Sense 5’-CTCGGAAGGACTATCCTGCTGCCAA-3’
Antisense 5’-GGCGCTCCAAGACGTTGTGTGTTCG-3’
 EGFR Sense 5’ GAATTCGGATGCAGAGCTTC-3´
Antisense 5´GACATGCTGCGGTGTTTTC-3‘
 PIK3CA Sense 5’-AAATGAAAGCTCACTCTGGATTCC-3’
Antisense 5’- TGTGCAATTCCTATGCAATCG-3’
 HHB Sense 5’-AGCAACCTCACAAACAGACACC-3’
Antisense 5’-CTACACATGCCCAGTTTC-3’
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Graphic 1. Comparison of gene copy numbers of EGFR (panel A), PIK3CA (Panel B), and C-myc (Panel C)
in tumor and normal lung samples. The p values shown were obtained with the Wilcoxon signed rank test.
The corresponding ROC curves, constructed considering the tumor character as the «positive value» are
shown at the bottom of each panel. An AUC value close to 1 indicates great sensitivity and specificity of
the marker at tumor/normal discrimination.
confirmed by the Wilcoxon p value obtained (p<0,0001).
Although dose values locate within a narrower range
than EGFR, the significance has a similar magnitude
order (Graphic 1, Panel A). AUC in the ROC curve was
higher than 0,9 indicating a good tumor/normal
discrimination capacity (Graphic 1, Panel B).
Although the graph corresponding to oncogene C-
myc indicates a similar behavior, the p value obtained at
the Wilcoxon test was 0,00083 (Graphic 1, Panel C).
This P value is 5 magnitude orders less significant than
the values obtained for EGFR and PIK3CA. The AOC
of the ROC graph is also lower indicating a low capacity
of this gene as neoplasm marker.
The ROC analysis allows an estimation of the best
threshold for discrimination between normal and tumor
samples with each marker gene by maximizing the
number of true positives and negatives. The best threshold
gene doses, based on this group of patients, generated
by this analysis for the three genes are presented in
Table 3.
We wanted to evaluate marker performance when
considering only DNA isolates from patients with the
same lung cancer subtype. Graphic 2 presents the gene
dose results for ADs and SQs separately. Graphic 2,
Panels A and B shows the distribution of the gene dose
of EGFR and PIK3CA. Both genes continue to be good
markers of the two groups of tumors (p<0,0001).
However, the p value obtained at the assay with C-myc
in ADs was 0,0033; indicating a lower significance of
the assay. With SQs, the discrimination was null
(p=0,8168).
Possible correlations between quantitative variables
can be observed by means of the Spearman
nonparametric test. Here, Spearman test was used to
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search for any influence of the age of the patients on the
results. Calculation of the Spearman rho coefficient did
not revealed any influence of this variable (-0,5<ρ<0,5).
However, a positive association between EGFR and
PIK3CA gene doses was found (ρ=0.75). It was a
frequent characteristic among our cases to find these
two genes at increased gene doses simultaneously.
None of them showed such correlation with C-myc.
Although clinical information about the cases was
fragmentary, given case antiquity, a common available
data was the presence of metastasis. The presence of
metastasis was a characteristic notably associated with
an increase in the genomic dose of C-myc, that was not
found with EGFR or PIK3CA. Nine out of twelve cases
with positive amplification also had metastasis. Two of
the three remaining cases were diagnosed as carcinoids
(Table 1), which are known by their low metastasis rate.
Both EGFR and PIK3CA were found with increased
gene doses in the two carcinoids of this study. On the
contrary, C-myc had a dose close to that of HHB in these
cases.
There were also two cases diagnosed as large cell
carcinoma (LCC) that demonstrated very high increases
of dose for the three genes. The only SCC included
Table 3
Frequency of DNA isolates cases with gene dose higher than the corresponding
ROC threshold
    n = 30                      ROC*Threshold                                       Origin (%)
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Graphic 2. Distribution of the gene dose parameter in ADs and SQ tumor and normal samples for EGFR,
PIK3CA and C-myc. The solid horizontal line indicates the median of each group. While tumor/normal
discrimination is clear with EGFR and PIK3CA, discrimination power of C-myc is lower, mainly in SQs.
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demonstrated the highest C-myc dose of the group
(Table 1). SCCs are very aggressive cancers with high
metastasis rate, which is compatible with the general
tendency found here. This particular case was  metastatic
to the pleura, pancreas, ovary, pericardium, and adrenal
glands.
DISCUSSION
The three genes analyzed have important functions
at regulation of cell responsiveness to external pro-
apoptotic signals, as part of the PIK3CA/Akt signaling
pathway. Several signaling proteins involved in this
pathway with likely oncogenic potential, have been
reported as amplified genes in cancer11-14. EGFR (ErbB1)
belongs to the ErbB family which also includes Her2/
neu (ErbB2), ErbB3 and ErbB4. They usually localize to
the membrane forming homo or heterodimers which
have the epidermal growth factor receptor (EGF) as
main ligand. Binding of the ligand induces the ATPase
activity of the cytoplasmic domain, triggering signal
transduction. PIK3CA after being activated by the
membrane complex transfers a phosphate group to the
phosphatidil inositol (4,5)-diphosphate producing a (4, 5,
6) phosphorylated product which promotes AKT proteins
recruiting to the sub membrane region. These events
determine antiapoptotic signals to reach the nucleus
continuously11. An increase in the function of these
components contributes to cell cycle progression.
Several treatment strategies try to control the function
of these components, mainly the receptors of EGF,
EGFR and Her2/neu. Since drug efficiency frequently
depends on an efficient interaction with the target
molecule, cells with increased expression of the target
are intrinsically more sensitive to drug action15. However,
other features such as certain mutations or the gene
dose have also an important influence16. Gene dose
characterization is one of the possible tools to correctly
classify the cases so that individualized treatment
programs lead to higher response rates and longer
survival17.
These results confirm EGFR dose measurement
potential as tumor phenotype marker in DNA isolates
from lung cancer patients. The ROC analysis for EGFR
demonstrated great sensitivity and specificity as neoplasm
marker. EGFR gene copy number is a parameter
frequently considered to personalize the treatment
because it is frequently determinant of the efficacy of
some drugs used in chemotherapy18. According to our
experience, in Colombian cases it is also frequent to find
increases in EGFR gene dose; however, it is not defined
yet if this property determines drug efficiency.
Considering individual EGFR sequence mutations, as
previously found19, or different types of markers such as
methylated CpG islands in addition to gene dose
variations could provide additional criteria to improve
treatment success.
PIK3CA demonstrated a similar potential, according
to its ROC curve. Copy number increase is a frequent
event in ovarian cancer20. However, the study by
Okudela et al.14, in lung cancer reported frequency of
PIK3CA amplification among Japanese patients in only
18,3% of the cases. That study concluded that both the
PIK3CA dose increase and the presence of certain
mutations are events with oncogenic potential, but
mutually exclusive14. In the present group of cases
PIK3CA copy number was 93% (Table 3). Different
exposures to environmental factors are likely the
explanation to observed differences between developed
and non developed countries. This fact implies that
genomic alteration associated to lung cancer
development may significantly differ between different
locations, so that molecular markers performing well in
a given population could be useless in another population,
justifying future studies seeking for a complete
characterization of the genetic behavior associated to
cancer advent under local conditions. Regarding C-myc,
its copy number was found frequently increased in
tumor samples from our patients; however, the ROC-
AUC demonstrated lower sensitivity and specificity.
In order to construct frequency tables discriminating
samples with high and low gene copy numbers, the best
threshold determined by the ROC analysis for each
gene as cutoff was taken. The results are shown in
Table 3. Calculation of these thresholds are based only
on the present group of patients; if a more widely usable
value is to be determined, it is necessary to do a similar
analysis with an statistically really significant number of
patients. Thresholds presented here are just reference
values for those studies. However, the new thresholds
that would be defined for Colombian population will
become useful screening tools for detection in more
accessible samples like blood or sputum.
ADs and SQ belong to a large category of lung
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cancers known as NSCLCs. Large cell lung carcinomas
(LCLC) are also included in this category, but they are
frequently considered as tumors which have lost their
initial differentiation so that the original AD or SQ
morphology is not easy recognizable. The two cases in
our group of cases demonstrated very high dose increases
for the genes evaluated (Table 1), suggesting that these
kind of molecular alterations continue to increase as the
neoplasm progresses. These makes sense in cancer
development is observed as a micro-evolutive process
where selection occurs so that cell lineages with more
marked proliferative and survival features end up
predominating among survivors21. To harbor oncogenes
at increased copy numbers is a characteristic that is
conserved as the neoplasm evolves.
Our study revealed a significant co-variation between
EGFR and PIK3CA gene doses not only by coincidence
of the amplified state but, within each gene range, the
magnitude of the phenomenon. This supports the idea
that the components of a signaling pathway should be
similarly affected for a real modification of the strength
of the signal to occur. This observation has been previously
made for the PIK3CA/Akt signaling pathway22. It is
necessary to perform similar research on other
components of the pathway like the AKT proteins and
protein kinase B (PKB), in order to find other possible
markers for cancer detection. The analysis of PKB
function in NSCLC has already been found to correlate
with PIK3CA gene dose22.
Even though our evidence is not conclusive, behavior
of C-myc in NSCLCs was found to be associated with
the presence of metastasis. This hypothesis must be
more clearly demonstrated in future studies. Identification
of molecular markers clearly associated with clinical
features of patients is a promising research line that will
eventually lead to achieve a close monitoring of cases
and will provide additional tools for personalized
treatment.
Development of a reliable tool for cancer detection
based on molecular alterations will require evaluating a
large number of candidate genes and the definition of an
adequate panel of markers that could include epigenetic
markers like methylated genes.
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